This was what the research review on nootropics indicated is mostly the case. I’ve also encountered a similar conclusion in many other areas. Enough so that my prior in new domains is now that you can cut off the tail of bad outcomes but can’t do much to the upside.
This was what the research review on nootropics indicated is mostly the case. I’ve also encountered a similar conclusion in many other areas. Enough so that my prior in new domains is now that you can cut off the tail of bad outcomes but can’t do much to the upside.